Orchid Pharma Limited will conduct an investor roadshow in Singapore from July 29, 2026, to July 31, 2026. The event aims to engage with investors through physical group meetings led by Mr. Mridul Dhanuka, Whole Time Director of the company. This engagement provides institutional and retail investors with a direct channel to discuss the company’s strategic outlook and operational performance without the disclosure of unpublished price-sensitive information (UPSI).

The announcement was made pursuant to Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. The intimation was submitted to both the National Stock Exchange of India Limited and BSE Limited on July 25, 2026. Kapil Dayya, Company Secretary & Compliance Officer, signed the disclosure.

Roadshow Schedule

The investor roadshow is structured as a series of physical group meetings over three days. The specific details are as follows:

Mr. Mridul Dhanuka will represent the company throughout these sessions. The schedule remains subject to change due to unforeseen exigencies on the part of investors or the company, with any modifications to be communicated subsequently.

Compliance and Disclosure Standards

Orchid Pharma Limited explicitly stated that no Unpublished Price Sensitive Information is proposed to be shared during the investor meet. This assurance aligns with regulatory requirements to maintain market integrity and prevent insider trading risks associated with selective disclosure. The company has requested stock exchanges to take the intimation on record, ensuring transparency for all stakeholders.

What the Numbers Show

While this filing does not contain financial metrics, the decision to hold a multi-day physical roadshow in Singapore signals active investor relations efforts. Such events are typically timed to coincide with broader market sentiment or post-result clarifications, allowing management to address queries directly. The absence of UPSI indicates that all material financial data available to the public is already reflected in prior disclosures.

Orchid Pharma announced that its scheme of amalgamation with Dhanuka Laboratories Limited became effective on July 10, 2026. The merger, sanctioned by the National Company Law Tribunal (NCLT), Chennai, was finalized after the companies filed the certified copy of the NCLT order with the Registrar of Companies, Chennai. Consequently, Dhanuka Laboratories has amalgamated with Orchid Pharma and dissolved without being wound up. The Board of Directors approved the effectiveness of the scheme at its meeting held on July 10, 2026.

The appointed date for the scheme is April 01, 2024. The authorized share capital of Orchid Pharma has automatically increased to ₹164,51,00,000, divided into 16,45,10,000 equity shares of ₹10 each, following the transfer of Dhanuka Laboratories' authorized capital. Clause V of the Memorandum of Association has been updated to reflect this change.

In consultation with the amalgamating company, the record date for determining eligible shareholders for the share issuance under the scheme is fixed as Thursday, July 23, 2026. The share exchange ratio stipulates that 161 fully paid-up equity shares of face value ₹10 each in Orchid Pharma will be issued and allotted to members of Dhanuka Laboratories for every 5 fully paid-up equity shares of face value ₹100 each held in Dhanuka Laboratories.

The intimation was submitted to the National Stock Exchange of India Limited and BSE Limited in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The filing follows an earlier intimation regarding the NCLT order. Kapil Dayya, Company Secretary & Compliance Officer of Orchid Pharma, signed the disclosure.

Key Details of the Amalgamation